In this episode of the podcast Progress, Potential, and Possibilities, Senior Scientist Luba Perry, PhD discusses ReConstruct, a technology developed at the Wyss that uses living, bioengineered tissue created from the patient’s own cells, to provide a safer, more natural reconstruction alternative for cancer survivors. #CancerResearch #3DPrinting #TissueEngineering Listen and watch: https://lnkd.in/gtFzuZ8j
Wyss Institute at Harvard University
Biotechnology Research
Boston, MA 57,919 followers
About us
At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.
- Website
-
http://wyss.harvard.edu
External link for Wyss Institute at Harvard University
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, MA
- Type
- Nonprofit
- Specialties
- Robotics, Bioengineering, Microfluidics, Medicine, Materials Science, Medical Devices, Synthetic Biology, Cell biology, Tissue engineering, Cancer research, Molecular engineering, Organ Engineering, Genome Editing, Molecular Robotics, and Immunomaterials
Locations
-
Primary
201 Brookline Ave.
Boston, MA 02215, US
Employees at Wyss Institute at Harvard University
-
Gangadhar Jogikalmath
Co-Founder Return To Vendor (RTV)
-
Ayis Antoniou
Entrepreneur/mentor/experienced, impactful, innovative leader/strategic advisor looking to connect with early-stage companies in bio-tech
-
James Gorman, M.D., Ph.D.
-
Samir Mitragotri
Professor @ Harvard University | Hiller Professor of Bioengineering | Hansjorg Wyss Professor of Biologically Inspired Engineering | Wyss Institute
Updates
-
DNA nanoswitch calipers are a first-of-their-kind research tool that leverage DNA’s unique molecular qualities to study post-translational modifications on proteins to unlock a new frontier of medicine. Learn more about this technology: https://lnkd.in/eXbGdB6F Andy W. Prakash Shrestha
-
We love seeing our breakthrough discoveries changing the world outside the lab! To celebrate #WorldFoodDay, we went to Clover Food Lab to try out some plant-based "meats" from Wyss startup Tender Food. Tender is commercializing a Wyss nanofiber-spinning technology to produce alternative meats whose texture is more like the real thing. #Sustainability #PlantBasedMeat #Vegetarian #Vegan #Startup
-
We're thrilled to announce that Kwasi Adu-Berchie, a member of our Advanced Technology Team, has been named a 2024 #STATWunderkind by STAT in recognition of his groundbreaking work engineering biomaterials for improved T-cell therapies and malaria vaccines. Learn more about Kwasi's work here: https://lnkd.in/eGtam7Xr
-
Congratulations to the Wyss' Brain Targeting Program on receiving a grant from the State of Massachusetts and Massachusetts Life Sciences Center (MLSC) as part of the MLSC Novel Therapeutics Delivery program. This is their second grant from the program. The MLSC Novel Therapeutics Delivery program supports interdisciplinary, translational projects focused on addressing complex problems in therapeutics delivery. #BrainTargetingProgram #Grants #Collaboration https://lnkd.in/e3nQm-PF
-
"As we look at the field [of tissue engineering and organ manufacturing] in general, I don’t believe it’s a question of if anymore. It’s a question of when we’re going to see this in the clinic," says Paul Stankey in a recent interview about co-SWIFT, a technology developed in Jennifer Lewis' lab. Read more from BioTechniques to learn how they developed this novel printing method that creates branching vessels in heart tissue that replicates the structure of human vasculature, the associated challenges, and what this work means for the future. https://bit.ly/4eZZ5JJ
-
What if we could reverse aging? Ichor is a Wyss project that aims to address age-related diseases using high-throughput genetic screening to identify networks of genes that are strongly implicated in aging processes and develop RNA-based therapies that can make old cells young again. #Aging #FibroticDiseases #Therapeutics https://lnkd.in/eXZd6Q8J
Ichor: Reversing Aging
https://wyss.harvard.edu
-
The HarborSite genome editing technology, developed at the Wyss, uses highly specific and efficient recombinase enzymes and genomic safe harbors to achieve more predictable, safe, and durable gene therapies for diseases of liver, blood, lung, skin, and other tissues. https://lnkd.in/eWtXt23t
HarborSite: Precise and Efficient Gene Editing for Next-Generation Gene Therapies
https://wyss.harvard.edu
-
Congratulations to Wyss startup Unravel Biosciences on moving to a new, expanded headquarters that will enable them to continue their work addressing therapeutics for patients with complex and rare diseases. Earlier this year, they initiated a clinical study in collaboration with Vanderbilt University Medical Center to evaluate vorinostat (RVL-001), an FDA-approved drug predicted by Unravel's BioNAV platform as a potential treatment for Rett syndrome. Rett syndrome is a rare genetic disease that causes debilitating physical and mental problems in the approximately 10,000 patients who are born with it every year and has no cure or treatment #RettSyndromeAwarenessMonth #Startups #Therapeutics #RareDisease
We are thrilled to announce the opening of Unravel Biosciences' new, expanded HQ in Medford, MA, marking a major milestone in our mission to develop effective therapeutics for patients, no matter how complex or rare their disease. This new facility will greatly enhance and grow our research and development capabilities, enabling us to accelerate the discovery of therapeutics for more patients in need. It takes a village to build a startup, and we are grateful to the incredible support we received from the New England biotech and university communities and our dedicated partners. Thanks to Wyss Institute at Harvard University Director and Co-Founder Donald Ingber, M.D., Ph.D., Representative Paul Donato, Medford Mayor Breanna Lungo-Koehn, MassBio President Kendalle Burlin O'Connell, The Jackson Laboratory VP Madeleine Braun, Ph.D., MBA, and Zymo Research Corp VP Keith Booher for attending. Additionally, the many families and foundation leaders who graciously joined our celebration and the heartwarming story of June's positive response thanks to Unravel's personalized data analysis was a meaningful reminder of why we put #patientsfirst. We’re looking forward to pushing the boundaries of science and making a meaningful difference for the rare disease community. Thank you to everyone who honored and supported us by attending our opening celebration! https://lnkd.in/gc-aGkJE #RareDisease #Therapeutics #Startup #DrugDevelopment
-
+5
-
As we near the end of #HispanicHeritageMonth, we're highlighting Nuria Lafuente Gómez, PhD, a postdoctoral fellow from Spain! She explains that she loves eating Spanish dishes because, "These flavors aren’t just food, they’re a warm reminder of home, where food is part of our identity, and we deeply cherish the time spent around the table."